Terry M Therneau

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7894538/terry-m-therneau-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94 papers	3,531 citations	29 h-index	58 g-index
101 ext. papers	4,645 ext. citations	6.6 avg, IF	5.27 L-index

#	Paper	IF	Citations
94	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.. *Brain Communications*, **2022**, 4, fcac017	4.5	2
93	Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation.. *BMC Cancer*, **2022**, 22, 221	4.8	0
92	Response to "On the reproducibility of quantitative susceptibility mapping and its potential as a clinical biomarker: A comment on Cogswell et al. 2021".. *NeuroImage*, **2022**, 251, 118992	7.9	
91	Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1915-1924.e6	6.9	19
90	NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages. *Annals of Neurology*, **2021**, 89, 1145-1156	9.4	8
89	BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study. *Hpb*, **2021**, 23, 762-769	3.8	2
88	Longitudinal cohorts for harnessing the electronic health record for disease prediction in a US population. *BMJ Open*, **2021**, 11, e044353	3	2
87	Natural History of Nonalcoholic Fatty Liver Disease With Normal Body Mass Index: A Population-Based Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	7
86	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. *NeuroImage*, **2021**, 224, 117433	7.9	13
85	Association of Initial Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. *JAMA Neurology*, **2021**, 78, 217-228	17.2	13
84	Analysis of time-to-event for observational studies: Guidance to the use of intensity models. *Statistics in Medicine*, **2021**, 40, 185-211	2.3	7
83	Using machine learning to improve the accuracy of patient deterioration predictions: Mayo Clinic Early Warning Score (MC-EWS). *Journal of the American Medical Informatics Association: JAMIA*, **2021**, 28, 1207-1215	8.6	1
82	Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis. *European Radiology*, **2021**, 1	8	1
81	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. *NeuroImage*, **2021**, 238, 118259	7.9	4
80	Relationships between amyloid and tau in an elderly population: An accelerated failure time model. *NeuroImage*, **2021**, 242, 118440	7.9	1
79	The impact of arm lymphedema on healthcare utilization during long-term breast cancer survivorship: a population-based cohort study. *Journal of Cancer Survivorship*, **2020**, 14, 347-355	5.1	4
78	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. *Blood Cancer Journal*, **2020**, 10, 39	7	1

77	Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations. *Clinical Trials*, **2020**, 17, 285-294	2.2	14
76	Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma. *Hepatology*, **2020**, 72, 1298-1309	11.2	8
75	Neurological safety of oxaliplatin in patients with uncommon variants in Charcot-Marie-tooth disease genes. *Journal of the Neurological Sciences*, **2020**, 411, 116687	3.2	1
74	Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation. *Clinical Immunology*, **2020**, 211, 108342	9	3
73	Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records. *Journal of Biomedical Informatics*, **2020**, 102, 103364	10.2	24
72	Predicting future rates of tau accumulation on PET. *Brain*, **2020**, 143, 3136-3150	11.2	25
71	The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery. *Hepatology*, **2020**, 71, 510-521	11.2	39
70	The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. *Journal of Hepatology*, **2019**, 71, 1229-1236	13.4	79
69	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. *Brain*, **2019**, 142, 3230-3242	11.2	77
68	Comparative analysis of staging systems in AL amyloidosis. *Leukemia*, **2019**, 33, 811-814	10.7	15
67	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. *JAMA - Journal of the American Medical Association*, **2019**, 321, 2316-2325	27.4	115
66	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. *Neurology*, **2019**, 93, e29-e39	6.5	36
65	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. *Blood Cancer Journal*, **2019**, 9, 49	7	4
64	Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography. *European Radiology*, **2019**, 29, 5823-5831	8	24
63	Cognitive function and neuropathological outcomes: a forward-looking approach. *Journal of Neurology*, **2019**, 266, 2920-2928	5.5	2
62	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. *JAMA Neurology*, **2019**,	17.2	106
61	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. *Blood*, **2019**, 134, 4362-4362	2.2	
60	Entorhinal cortex tau, amyloid-β cortical thickness and memory performance in non-demented subjects. *Brain*, **2019**, 142, 1148-1160	11.2	49

59	Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer. *Mayo Clinic Proceedings*, **2019**, 94, 27-36	6.4	4
58	Predicting Progression to Mild Cognitive Impairment. *Annals of Neurology*, **2019**, 85, 155-160	9.4	18
57	Joint associations of amyloidosis and cortical thickness with cognition. *Neurobiology of Aging*, **2018**, 65, 121-131	5.6	21
56	Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease. *Inflammatory Bowel Diseases*, **2018**, 24, 1815-1825	4.5	11
55	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. *Mayo Clinic Proceedings*, **2018**, 93, 739-746	6.4	16
54	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. *Brain*, **2018**, 141, 271-287	11.2	139
53	Longitudinal tau PET in ageing and Alzheimer's disease. *Brain*, **2018**, 141, 1517-1528	11.2	194
52	Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. *Hepatology*, **2018**, 67, 1726-1736	11.2	134
51	Application of multi-state models in cancer clinical trials. *Clinical Trials*, **2018**, 15, 489-498	2.2	20
50	The impact of pharmacokinetic gene profiles across human cancers. *BMC Cancer*, **2018**, 18, 577	4.8	1
49	Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values. *Scientific Reports*, **2018**, 8, 7421	4.9	5
48	Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. *World Journal of Gastroenterology*, **2018**, 24, 1321-1331	5.6	9
47	Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228	2.2	
46	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. *Blood*, **2018**, 132, 4458-4458	2.2	
45	Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. *Cancer Medicine*, **2018**, 7, 5870-5878	4.8	11
44	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. *Blood Cancer Journal*, **2018**, 8, 96	7	29
43	Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer. *Clinical Colorectal Cancer*, **2017**, 16, 115-123.e3	3.8	27
42	Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. *Liver Transplantation*, **2017**, 23, 733-740	4.5	23

41	Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population. *International Journal of Cardiology*, **2017**, 240, 379-385	3.2	24
40	Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis. *Liver Cancer*, **2017**, 6, 126-136	9.1	18
39	Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. *Lancet Neurology, The*, **2017**, 16, 435-444	24.1	174
38	Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?. *Journal of Rheumatology*, **2017**, 44, 732-739	4.1	47
37	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 205-216	1.2	358
36	Assessing calibration of prognostic risk scores. *Statistical Methods in Medical Research*, **2016**, 25, 1692-706	2.3	116
35	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. *Lancet Neurology, The*, **2016**, 15, 56-64	24.1	82
34	A Topic-modeling Based Framework for Drug-drug Interaction Classification from Biomedical Text **2016**, 2016, 789-798	0.7	5
33	Aspirin use and the risk of cholangiocarcinoma. *Hepatology*, **2016**, 64, 785-96	11.2	63
32	Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. *BMJ Open*, **2015**, 5, e006413	3	122
31	Measure of functional independence dominates discharge outcome prediction after inpatient rehabilitation for stroke. *Stroke*, **2015**, 46, 1038-44	6.7	52
30	Global transcriptional profiling using RNA sequencing and DNA methylation patterns in highly enriched mesenchymal cells from young versus elderly women. *Bone*, **2015**, 76, 49-57	4.7	27
29	Reply to: "Chronic kidney disease after liver transplantation". *Journal of Hepatology*, **2015**, 62, 244-5	13.4	
28	Prognostic Value of Model for End-Stage Liver Disease Score Measurements on a Daily Basis in Critically Ill Patients With Cirrhosis. *Mayo Clinic Proceedings*, **2015**, 90, 1196-206	6.4	4
27	Extending Association Rule Summarization Techniques to Assess Risk of Diabetes Mellitus. *IEEE Transactions on Knowledge and Data Engineering*, **2015**, 27, 130-141	4.2	29
26	Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma. *Cancer Medicine*, **2015**, 4, 1599-602	4.8	7
25	Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis. *Journal of Rheumatology*, **2015**, 42, 181-7	4.1	17
24	Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. *PLoS ONE*, **2015**, 10, e0138347	3.7	43

23	A new clinically based staging system for perihilar cholangiocarcinoma. *American Journal of Gastroenterology*, **2014**, 109, 1881-90	0.7	60
22	Comparative effectiveness of carotid revascularization therapies: evidence from a National Hospital Discharge Database. *Stroke*, **2014**, 45, 3311-9	6.7	24
21	Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. *Mayo Clinic Proceedings*, **2014**, 89, 1336-49	6.4	151
20	BIMA V3: an aligner customized for mate pair library sequencing. *Bioinformatics*, **2014**, 30, 1627-9	7.2	66
19	Metformin does not improve survival in patients with hepatocellular carcinoma. *World Journal of Gastroenterology*, **2014**, 20, 15750-5	5.6	21
18	Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. *Mayo Clinic Proceedings*, **2012**, 87, 1071-9	6.4	71
17	What Does PLIER Really Do?. *Cancer Informatics*, **2008**, 6, 117693510800600	2.4	19
16	Memories of Sam Wieand. *Lifetime Data Analysis*, **2008**, 14, 13-5	1.3	
15	Reply:. *Hepatology*, **2008**, 48, 688-688	11.2	2
14	What does PLIER really do?. *Cancer Informatics*, **2008**, 6, 423-31	2.4	15
13	Increased Risk of Monoclonal Gammopathy in First-Degree Relatives of Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.. *Blood*, **2008**, 112, 1672-1672	2.2	
12	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. *Blood*, **2006**, 108, 3493-3493	2.2	1
11	Immunoglobulin Free Light Chains at Diagnosis: Predictors of Progression and Survival in Solitary Plasmacytoma of Bone.. *Blood*, **2005**, 106, 5080-5080	2.2	1
10	Sharpening spots: correcting for bleedover in cDNA array images. *Mathematical Biosciences*, **2002**, 176, 1-15	3.9	6
9	Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. *Hepatology*, **2000**, 31, 456-60	11.2	78
8	A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders. *Leukemia and Lymphoma*, **2000**, 38, 345-50	1.9	5
7	Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. *British Journal of Haematology*, **1999**, 104, 131-7	4.5	50
6	Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. *Hepatology*, **1999**, 29, 644-7	11.2	186

5	Cost-effectiveness of ultrasound-guided liver biopsy. *Hepatology*, **1998**, 27, 1220-6	11.2	117
4	Optimal timing of liver transplantation for primary biliary cirrhosis. *Hepatology*, **1998**, 28, 33-8	11.2	83
3	DNA ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow cytometry. *Cytometry*, **1996**, 26, 253-9		5
2	Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside. *Medical and Pediatric Oncology*, **1989**, 17, 79-82		5
1	Optimal two-stage screening designs for survival comparisons		3